Investors in Adamas Pharmaceuticals (NASDAQ:ADMS) are off to a great week. The pharma play is getting picked up as part of an acquisition with biopharma company Supernus (NASDAQ:SUPN). The news this morning is fattening up the portfolios of ADMS stock holders. Source: luchschenF / Shutterstock.com Adamas is a California-based company that deals exclusively in treating neurological diseases.…